Premium
Incorporation of a lauric acid‐conjugated GRGDS peptide directly into the matrix of a poly(carbonate‐urea)urethane polymer for use in cardiovascular bypass graft applications
Author(s) -
Kidane Asmeret G.,
Punshon Geoffrey,
Salacinski Henryk J.,
Ramesh Bala,
Dooley Audrey,
Olbrich Michael,
Heitz Johannes,
Hamilton George,
Seifalian Alexander M.
Publication year - 2006
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.30817
Subject(s) - materials science , biocompatibility , polymer , self healing hydrogels , urea , polymer chemistry , nuclear chemistry , organic chemistry , chemistry , composite material , metallurgy
Gly–Arg–Gly–Asp–Ser (GRGDS) was modified by conjugation to lauric acid (LA) to facilitate incorporation into the matrix of a poly(carbonate‐urea)urethane (PCU) used in vascular bypass grafts. GRGDS and LA‐GRGDS were synthesized using solid phase Fmoc chemistry and characterized by high performance liquid chromatography and Fourier transform infrared spectroscopy. LA‐GRGDS was passively coated and incorporated as nanoparticle dispersion on the PCU films. Biocompatibility of the modified surfaces was investigated. Endothelial cells seeded on LA‐GRGDS coated and incorporated PCU showed after 48 h and 72 h a significant ( p < 0.05) increase in metabolism compared with unmodified PCU. The platelet adhesion and hemolysis studies showed that the modification of PCU had no adverse effect. In conclusion, LA‐conjugated RGD derivatives, such as LA‐GRGDS, that permit solubility into solvents used in solvent casting methodologies should have wide applicability in polymer development for use in coronary, vascular, and dialysis bypass grafts, and furthermore scaffolds utilized for tissue regeneration and tissue engineering. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006